Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma

NCT00827359 is registered in ClinicalTrials.gov with Beth Israel Deaconess Medical Center as lead sponsor.

NCT NCT00827359
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00827359 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma
Lead sponsor
Beth Israel Deaconess Medical Center
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2009
Completion date
June 30, 2018
Enrollment
25 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

renal cancer, renal cell carcinoma